瑞科生物-B(02179)发布中期业绩，股东应占亏损3.41亿元，同比扩大36.7%

Core Viewpoint - 瑞科生物-B (02179) reported a significant increase in revenue for the first half of 2025, primarily due to income generated from granting intellectual property licenses, despite a substantial loss for the period [1] Financial Performance - Revenue from continuing operations reached 10.899 million RMB, compared to none in the same period last year [1] - The loss attributable to equity holders of the parent company was 341 million RMB, representing a year-on-year increase of 36.7% [1] - Basic loss per share was 0.71 RMB [1]